Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing

Reuters

08/19

Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing

Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab $(BOT.AU)$ and balstilimab $(BAL.AU)$ program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer $(CRC)$ studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560419564"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560419564\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560419564?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560419564","market":"fut","top_or_hot":-1,"title":"Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab <a href=\"https://laohu8.com/S/BOT.AU\">$(BOT.AU)$</a> and balstilimab <a href=\"https://laohu8.com/S/BAL.AU\">$(BAL.AU)$</a> program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a> studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&amp;A, allowing for further engagement and clarification.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-19 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab <a href=\"https://laohu8.com/S/BOT.AU\">$(BOT.AU)$</a> and balstilimab <a href=\"https://laohu8.com/S/BAL.AU\">$(BAL.AU)$</a> program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a> studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&amp;A, allowing for further engagement and clarification.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉納斯公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL8zzVK2:1","article_id":"2560419564","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560419564","pubTimestamp":1755603034,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab  and balstilimab  program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer  studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"Agenus Inc.在即将举行的虚拟利益相关者简报会上宣布免疫肿瘤学领域的战略进展和关键里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    \n\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab $(BOT.AU)$ and balstilimab $(BAL.AU)$ program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer $(CRC)$ studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}